Ivermectin plus your current immunotherapy for solid tumors
Part of Cancer clinical trials.
This trial tests adding ivermectin (a common anti-parasitic drug) to your current immunotherapy. The hope is that ivermectin may help the immunotherapy work better against your cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a solid tumor cancer (not blood cancer).
- You are already on an immunotherapy drug (called an immune checkpoint inhibitor) for at least 3 weeks.
- You can swallow pills and don't have active digestive problems that would affect absorption.
- You are reasonably active (able to do light work and care for yourself).
- You are willing to use birth control or abstain from sex during the study and for 4 weeks after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether ivermectin, given together with immunotherapy (balstilimab or pembrolizumab), can help treat metastatic triple-negative breast cancer. It mainly looks at safety first, and may also explore how well the treatment works for people whose cancer has spread.
This trial tests a combination of two investigational drugs (IMM2510 and IMM01) that work with your immune system to fight cancer. It may help people with advanced solid tumors who have not responded to other treatments.
This trial tests whether adding mistletoe extract (Iscador) to standard immunotherapy can make the treatment safer and boost the immune system's response against advanced solid tumors (excluding skin cancer). If you are already receiving or about to start a checkpoint inhibitor, this study may help understand if the combination works better.
This trial tests a new immunotherapy drug called ivonescimab given together with standard chemotherapy for advanced stomach cancer. It may help your immune system fight the cancer more effectively.
This study tests a new drug (SYS6006) combined with an existing immunotherapy (called Enlonstobart) to see if it works better than the immunotherapy alone for people with advanced solid tumors. It may help shrink or slow the growth of your cancer.
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.